keyword
MENU ▼
Read by QxMD icon Read
search

Bioresorbable scaffolds

keyword
https://www.readbyqxmd.com/read/29027096/new-innovations-in-drug-eluting-stents-for-peripheral-arterial-disease
#1
REVIEW
Roi Altit, William A Gray
PURPOSE OF REVIEW: The purpose of this paper was to provide a review of the burden of peripheral arterial disease; to examine older therapies and their limitations; and especially to highlight new treatment innovations as well as the data supporting their use. RECENT FINDINGS: Building on the success of paclitaxel in the prevention of restenosis in the peripheral circulation, the newest generation drug-eluting stent is presented, which combines paclitaxel with a polymer-allowing the drug to be eluted slowly over 12 months...
October 12, 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/29020300/impact-of-design-of-coronary-stents-and-length-of-dual-antiplatelet-therapies-on-ischaemic-and-bleeding-events-a-network-meta-analysis-of-64-randomized-controlled-trials-and-102%C3%A2-735-patients
#2
Fabrizio D'Ascenzo, Mario Iannaccone, Gaelle Saint-Hilary, Maurizio Bertaina, Stefanie Schulz-Schüpke, Cheol Wahn Lee, Alaide Chieffo, Gerard Helft, Sebastiano Gili, Umberto Barbero, Giuseppe Biondi Zoccai, Claudio Moretti, Fabrizio Ugo, Maurizio D'Amico, Roberto Garbo, Gregg Stone, Sara Rettegno, Pierluigi Omedè, Federico Conrotto, Christian Templin, Antonio Colombo, Seung-Jung Park, Adnan Kastrati, David Hildick-Smith, Mauro Gasparini, Fiorenzo Gaita
Aims: The differential impact on ischaemic and bleeding events of the type of drug-eluting stent [durable polymer stents [DES] vs. biodegradable polymer stents vs. bioresorbable scaffolds (BRS)] and length of dual antiplatelet therapy (DAPT) remains to be defined. Methods and results: Randomized controlled trials comparing different types of DES and/or DAPT durations were selected. The primary endpoint was Major Adverse Cardiovascular Events (MACE) [a composite of death, myocardial infarction (MI), and target vessel revascularization]...
August 11, 2017: European Heart Journal
https://www.readbyqxmd.com/read/29020259/report-of-an-esc-eapci-task-force-on-the-evaluation-and-use-of-bioresorbable-scaffolds-for-percutaneous-coronary-intervention-executive-summary
#3
Robert A Byrne, Giulio G Stefanini, Davide Capodanno, Yoshinobu Onuma, Andreas Baumbach, Javier Escaned, Michael Haude, Stefan James, Michael Joner, Peter Jüni, Adnan Kastrati, Semih Oktay, William Wijns, Patrick W Serruys, Stephan Windecker
A previous Task Force of the European Society of Cardiology (ESC) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) provided a report on recommendations for the non-clinical and clinical evaluation of coronary stents. Following dialogue with the European Commission, the Task Force was asked to prepare an additional report on the class of devices known as bioresorbable scaffolds (BRS). Five BRS have CE-mark approval for use in Europe. Only one device-the Absorb bioresorbable vascular scaffold-has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2-3 years...
August 28, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28988950/experience-with-the-absorb-bioresorbable-vascular-scaffold-in-various-scenarios-of-congenital-heart-disease
#4
Alejandro Rodríguez Ogando, Fernando Ballesteros Tejerizo, Fernando Sarnago Cebada, Constancio Medrano López, Juan Miguel Gil Jaurena, José Luis Zunzunegui Martínez
No abstract text is available yet for this article.
October 5, 2017: Revista Española de Cardiología
https://www.readbyqxmd.com/read/28977391/improvement-in-local-haemodynamics-5%C3%A2-years-after-implantation-of-a-coronary-bioresorbable-scaffold-a-pulsatile-non-newtonian-shear-stress-analysis
#5
Vikas Thondapu, Erhan Tenekecioglu, Eric K W Poon, Yoshinobu Onuma, Patrick W Serruys
No abstract text is available yet for this article.
July 18, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28966157/characteristics-and-outcome-of-patients-with-complex-coronary-lesions-treated-with-bioresorbable-scaffolds-three-years-follow-up-in-a-cohort-of-consecutive-patients
#6
Remzi Anadol, Liv Lorenz, Melissa Weissner, Helen Ullrich, Alberto Polimeni, Thomas Münzel, Tommaso Gori
AIMS: The safety of bioresorbable scaffolds (BRS) has recently been challenged. It is however unclear whether outcomes depend on the complexity of the lesion or on the technique used to implant BRS. METHODS AND RESULTS: This investigator-initiated, single-center, single-arm observational study recruited 657 consecutive patients (79% males, 66.7% acute coronary syndromes, age 63±12 years). Three-hundred twenty-two lesions (42.3%) in 297 (45.2%) patients with type B2 or C lesions were classified as "complex lesions group"...
October 3, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28966155/one-year-clinical-outcomes-after-unrestricted-implantation-of-absorb-bioresorbable-scaffold-rai-registry
#7
Alfonso Ielasi, Bernardo Cortese, Elisabetta Moscarella, Bruno Loi, Giuseppe Tarantini, Attilio Varricchio, Francesco Pisano, Alessandro Durante, Giampaolo Pasquetto, Alessandro Colombo, Gabriele Tumminello, Luciano Moretti, Paolo Calabrò, Pietro Mazzarotto, Maurizio Tespili, Donatella Corrado, Giuseppe Steffenino
AIMS: to assess the outcomes following Absorb bioresorbable scaffold (BVS) implantation in an unrestricted clinical practice according to an "on-label" versus "off-label" indication. METHODS AND RESULTS: RAI is a prospective registry, investigating the BVS performance in different lesions subsets. No specific exclusion criteria were applied. Co-primary end-points were target lesion revascularization (TLR) and definite/probable scaffold thrombosis (ScT) at one-year...
October 3, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28954592/long-term-outcomes-of-bioresorbable-vascular-scaffold-in-st-elevation-myocardial-infarction
#8
Quentin de Hemptinne, Fabien Picard, Hung Q Ly, Reda Ibrahim, Anita W Asgar, Pierre de Guise, Serge Doucet, Jean-François Dorval, Guillaume Marquis-Gravel, Michael Levi, Philippe L-L'allier, Jean-François Tanguay
BACKGROUND: Bioresorbable vascular scaffolds (BVS) implantation in selected patients with stable angina has been demonstrated feasible and safe. However, limited data are currently available on long-term outcomes after BVS implantation for ST-elevation myocardial infarction (STEMI). Therefore, we sought to assess the safety, efficacy and long-term results of BVS implantation in STEMI patients. METHODS: Retrospective review of all STEMI patients treated with the Absorb(®) BVS (Abbott Vascular, Santa Clara, CA) or conventional drug eluting stent (DES) between 1 April 2013 and 30 March 2014...
September 28, 2017: Acta Cardiologica
https://www.readbyqxmd.com/read/28954399/biodegradable-materials-and-metallic-implants-a-review
#9
REVIEW
Mythili Prakasam, Janis Locs, Kristine Salma-Ancane, Dagnija Loca, Alain Largeteau, Liga Berzina-Cimdina
Recent progress made in biomaterials and their clinical applications is well known. In the last five decades, great advances have been made in the field of biomaterials, including ceramics, glasses, polymers, composites, glass-ceramics and metal alloys. A variety of bioimplants are currently used in either one of the aforesaid forms. Some of these materials are designed to degrade or to be resorbed inside the body rather than removing the implant after its function is served. Many properties such as mechanical properties, non-toxicity, surface modification, degradation rate, biocompatibility, and corrosion rate and scaffold design are taken into consideration...
September 26, 2017: Journal of Functional Biomaterials
https://www.readbyqxmd.com/read/28948934/report-of-an-esc-eapci-task-force-on-the-evaluation-and-use-of-bioresorbable-scaffolds-for-percutaneous-coronary-intervention-executive-summary
#10
Robert A Byrne, Giulio F Stefanini, Davide Capodanno, Yoshinobu Onuma, Andreas Baumbach, Javier Escaned, Michael Haude, Stefan James, Michael Joner, Peter Ju Ni, Adnan Kastrati, Semih Oktay, William Wijns, Patrick W Serruys, Stephan Windecker
A previous Task Force of the European Society of Cardiology (ESC) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) provided a report on recommendations for the nonclinical and clinical evaluation of coronary stents. Following dialogue with the European Commission, the Task Force was asked to prepare an additional report on the class of devices known as bioresorbable scaffolds (BRS). Five BRS have CE-mark approval for use in Europe. Only one device - the Absorb bioresorbable vascular scaffold - has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2-3 years...
September 25, 2017: EuroIntervention
https://www.readbyqxmd.com/read/28948291/very-late-bioresorbable-vascular-scaffold-thrombosis-at-25-months-post-implantation
#11
Koo Hui Chan, Swee-Chong Seow, Huay Cheem Tan
No abstract text is available yet for this article.
September 2017: Singapore Medical Journal
https://www.readbyqxmd.com/read/28943146/impact-of-calcium-on-procedural-and-clinical-outcomes-in-lesions-treated-with-bioresorbable-vascular-scaffolds-a-prospective-brs-registry-study
#12
Jiang Ming Fam, Cordula Felix, Yuki Ishibashi, Yoshinobu Onuma, Roberto Diletti, Nicolas M Van Mieghem, Evelyn Regar, Peter De Jaegere, Felix Zijlstra, Robert Jan M van Geuns
BACKGROUND: There is limited data on the impact of calcium (Ca) on acute procedural and clinical outcomes in patients with lesions treated with bioresorbable vascular scaffolds (BRS). We sought to evaluate the effect of calcium on procedural and clinical outcomes in a 'real world' population. METHODS: Clinical outcomes were compared between patients with at least 1 moderately or heavily calcified lesion (Ca) and patients with no/mild calcified lesions (non-Ca) enrolled in our institutional BRS registry...
August 25, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28935086/coronary-artery-aneurysm-with-thrombosis-after-implantation-of-a-bioresorbable-coronary-artery-scaffold
#13
Rayyan Hemetsberger, Osman Gürocak, Mohamad Soud, Hector M Garcia-Garcia, Joachim Weber-Albers, Holger Nef, Helge Möllmann
No abstract text is available yet for this article.
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935085/early-collapse-of-a-magnesium%C3%A2-bioresorbable-scaffold
#14
Hector Cubero-Gallego, Bert Vandeloo, Josep Gomez-Lara, Rafael Romaguera, Gerard Roura, Joan A Gomez-Hospital, Angel Cequier
No abstract text is available yet for this article.
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935082/bioresorbable-vascular-scaffolds-in%C3%A2-women
#15
EDITORIAL
Gennaro Giustino, George D Dangas
No abstract text is available yet for this article.
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935081/efficacy-and-safety-of-the-absorb-bioresorbable-vascular-scaffold-in-females-and-males-results-of-an-individual-patient-level-pooled-meta-analysis-of-randomized-controlled-trials
#16
Satya Shreenivas, Dean J Kereiakes, Stephen G Ellis, Runlin Gao, Takeshi Kimura, Yoshinobu Onuma, Karine Piard-Ruster, Yunlong Zhang, Kai Koo, Minh-Thien Vu, Patrick W Serruys, Gregg W Stone
OBJECTIVES: Because females are under-represented in coronary trials, this study sought to assess the relative safety and efficacy of Absorb bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) and the Xience everolimus-eluting stent in females compared with males. BACKGROUND: The Absorb everolimus-eluting BVS provides drug delivery and mechanical support similar to a metallic drug-eluting stent, followed by resorption and restoration of more normal vascular structure with the potential to improve late clinical outcomes...
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935079/effect-of-post-dilatation-following-primary-pci-with-everolimus-eluting-bioresorbable-scaffold-versus-everolimus-eluting-metallic-stent-implantation-an-angiographic-and-optical-coherence-tomography-trofi%C3%A2-ii%C3%A2-substudy
#17
Kyohei Yamaji, Salvatore Brugaletta, Manel Sabaté, Andrés Iñiguez, Lisette Okkels Jensen, Angel Cequier, Sjoerd H Hofma, Evald Høj Christiansen, Maarten Suttorp, Gerrit Anne van Es, Yohei Sotomi, Yoshinobu Onuma, Patrick W Serruys, Stephan Windecker, Lorenz Räber
OBJECTIVES: This study sought to investigate the effect of post-dilatation on angiographic and intracoronary imaging parameters in the setting of primary percutaneous coronary intervention comparing the everolimus-eluting bioresorbable scaffold (BRS) with the everolimus-eluting metallic stent (EES). BACKGROUND: Routine post-dilatation of BRS has been suggested to improve post-procedural angiographic and subsequent device-related clinical outcomes. METHODS: In the ABSORB STEMI TROFI II trial, 191 patients with ST-segment elevation myocardial infarction were randomly assigned to treatment with BRS (n = 95) or EES (n = 96)...
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935078/bioresorbable-vascular-scaffold-implantation-to-whom-and-how
#18
EDITORIAL
Manel Sabaté
No abstract text is available yet for this article.
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935077/a-prospective-evaluation-of-a-pre-specified-absorb-bvs-implantation-strategy-in-st-segment-elevation-myocardial-infarction-the-bvs-stemi-strategy-it-study
#19
Alfonso Ielasi, Gianluca Campo, Claudio Rapetto, Attilio Varricchio, Bernardo Cortese, Salvatore Brugaletta, Salvatore Geraci, Paolo Vicinelli, Fortunato Scotto di Uccio, Gioel Gabrio Secco, Arnaldo Poli, Elisa Nicolini, Kohki Ishida, Azeem Latib, Maurizio Tespili
OBJECTIVES: The aim of this study was to assess the feasibility and clinical results following a pre-specified bioresorbable scaffold (Absorb BVS) implantation strategy in patients with ST-segment elevation myocardial infarction (STEMI). BACKGROUND: Concerns were raised about the safety of Absorb because a non-negligible rate of thrombosis was reported within 30 days and at midterm follow-up after primary percutaneous coronary intervention. METHODS: This was a prospective, multicenter study of patients with STEMI (<75 years of age with symptom onset <12 h) undergoing primary percutaneous coronary intervention with Absorb following a dedicated implantation protocol...
September 25, 2017: JACC. Cardiovascular Interventions
https://www.readbyqxmd.com/read/28935076/fantom-bioresorbable-scaffold-verse-but-not-yet-chorus-an-incomplete-composition
#20
EDITORIAL
Stephen G Ellis
No abstract text is available yet for this article.
September 25, 2017: JACC. Cardiovascular Interventions
keyword
keyword
77647
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"